Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ICEL > SEC Filings for ICEL > Form 8-K on 4-Nov-2013All Recent SEC Filings

Show all filings for CELLULAR DYNAMICS INTERNATIONAL, INC. | Request a Trial to NEW EDGAR Online Pro

Form 8-K for CELLULAR DYNAMICS INTERNATIONAL, INC.


4-Nov-2013

Entry into a Material Definitive Agreement, Regulation FD D


Item 1.01. Entry Into A Material Definitive Agreement.

On October 29, 2013, Cellular Dynamics International, Inc. ("CDI") and the California Institute for Regenerative Medicine ("CIRM") entered into an iPSC Derivation Agreement (the "Derivation Agreement"), which incorporates a Notice of Grant Award (the "NGA" and together with the Derivation Agreement, the "Agreement") relating to the previously announced $16 million grant awarded by CIRM to CDI.

The terms of the Agreement provide that:

CDI will use its episomal reprogramming technology to derive three induced pluripotent stem cell ("iPSC") lines from blood or skin samples from each of 3,000 different individuals.

CDI's work will be performed and funded by CIRM's $16 million grant over multiple years.

CDI will deposit the iPSC lines that CDI creates in the iPSC bank that the Coriell Institute for Medical Research ("Coriell") will maintain under CIRM's repository grant awarded to Coriell.

CIRM will own any intellectual property that is created by CDI in the course of performing its work under the Agreement and that covers any potential use of the iPSC lines by CIRM, Coriell or others.

CDI otherwise retains all of its intellectual property.

CDI will license or sublicense, according to the terms specified in the Agreement, certain intellectual property owned by or licensed to CDI to persons who receive any iPSC lines from the Coriell iPSC bank (a "Standard Form hiPSC License").

CIRM will require Coriell to not allow any person to receive any iPSC lines from the Coriell iPSC bank unless the person has entered into a Standard Form hiPSC License with CDI.

CDI anticipates that it will use its existing technology and intellectual property to perform its work under the Agreement.

The foregoing summary of the Derivation Agreement and the NGA does not purport to be complete and is qualified in its entirety by reference to such agreements, which are filed as Exhibit 10.1 and Exhibit 10.2 to this Current Report on Form 8-K and incorporated by reference herein.



Item 7.01. Regulation FD Disclosure.

On November 4, 2013 CDI issued a press release announcing the Agreement. A copy of CDI's press release is furnished as Exhibit 99.1 hereto.

The information in Item 7.01 of this Current Report on Form 8-K, including the information in Exhibit 99.1 hereto, is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed "filed" for any purpose, including for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section. The information in Item 7.01 of this Current Report on Form 8-K, including the information in Exhibit 99.1 hereto, shall not be deemed incorporated by reference into any filing under the Securities Act, or the Exchange Act regardless of any general incorporation language in such filing.

Item 9.01.            Financial Statements and Exhibits

(d)        Exhibits

           Exhibit No                               Description
                10.1      iPSC Derivation Agreement dated as of October 25, 2013 by and
                           between
                           the California Institute for Regenerative Medicine and
                           Cellular Dynamics
                           International, Inc.

                10.2      Notice Of Grant Award dated as of October 25, 2013 by and
                           between the
                           California Institute for Regenerative Medicine and Cellular
                           Dynamics
                           International, Inc.

                99.1       Press Release

Registrant has omitted portions of the referenced exhibit and filed such exhibit separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 24b-2 promulgated under the Securities Exchange Act of 1934.

  Add ICEL to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ICEL - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.